The goal of this Phase 3 randomized clinical trial is to compare the efficacy and safety of Belantamab Mafodotin, Pomalidomide, and Dexamethasone against Bortezomib, Pomalidomide, and Dexamethasone.
This trial is currently open and accepting patients.
This study is seeking to enroll approximately 450 participants.
Participants will be randomly assigned into one of two different groups (also called treatment arms). This study is open label, which means that participants and their doctors will know which group they have been placed in.
The following criteria is a partial list of reasons why patients may be eligible to participate in this clinical trial. Further evaluation with a medical professional is required.
Enrollment: 300 patients (estimated)View More
View all clinical trial locations sorted by state.
We know how difficult and confusing this process can be. If you are interested in this clinical trial or have questions, you can call us at any time. You can also send us a direct message with questions.(888) 828-2206
If you are interested in keeping an eye on this trial, you can add it to your list of favorite trials. We'll send you alerts when this trial is updated.
You can explore trial locations from around the US and connect directly with a trial coordinator.Find Nearby Locations
You can print an overview of this trial to take in to your next appointment. Your doctor can help you understand if this trial may be right for you.
Still need help? Send us a message
SparkCures is working closely with GlaxoSmithKline to provide the most up-to-date information on this clinical trial. Use the button above to add this trial to your list of favorites.
Learn more about how we work with trial sponsors